Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival

1 May 2019

Abstract excerpt

Abstract Background In 2016, the World Health Organization reclassified the definition of glioblastoma (GBM), dividing these tumors into isocitrate dehydrogenase (IDH)-wild-type and IDH-mutant GBM, where the vast majority of GBMs are IDH-wild-type. Nomograms are useful tools for individualized estimation of survival. This study aimed to develop and independently validate a nomogram for IDH-wild-type patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Glioma Diagnosis and Treatment
Share to Radiomics and Machine Learning in Medical Imaging

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31608326
DOI: 10.1093/noajnl/vdz007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survivalPMID 31608326Read ↗

Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastomaSemantic proximity Read ↗

Survival Impact of Isocitrate Dehydrogenase (IDH)-Wildtype Histological Versus Molecular Glioblastoma: A Propensity Score-Matched AnalysisSemantic proximity Read ↗

A prognostic model of newly diagnosed glioblastoma based on clinical characteristicsSemantic proximity Read ↗

Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant GlioblastomaSemantic proximity Read ↗

Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and TherapySemantic proximity Read ↗

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumorsSemantic proximity Read ↗

Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT.Semantic proximity Read ↗

Clinical measures, radiomics, and genomics offer synergistic value in AI-based prediction of overall survival in patients with glioblastomaSemantic proximity Read ↗

A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing.Semantic proximity Read ↗

Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1Semantic proximity Read ↗

Multi-Omic Prediction of Overall Survival in Patients With Glioblastoma: Additive and Synergistic Value of Clinical Measures, Radiomics, and GenomicsSemantic proximity Read ↗

A radiomics-clinical nomogram for preoperative prediction of IDH1 mutation in primary glioblastoma multiforme.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.